CONMED (NYSE: CNMD) EVP granted RSUs and stock options in 2026 award

Rhea-AI Filing Summary

CONMED Corp executive Brent Lalomia reported equity awards that increase his stake-based compensation. On March 2, 2026, he acquired 9,554 RSUs, each representing one future share of common stock, and 11,322 stock options granted at no cost per option.

The RSUs generally vest over three years in 33%, 33%, and 34% annual installments, while the options generally vest in four equal annual installments. Both awards were granted under CONMED’s 2025 Long-Term Incentive Plan, tying a portion of his compensation to the company’s longer-term performance.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Lalomia Brent

Role Executive VP RA, QA

Type	Security	Shares	Price	Value
Grant/Award	RSUs (Restricted Stock Units)	9,554	$0.00	--
Grant/Award	Options To Purchase Common Stock	11,322	$0.00	--

Holdings After Transaction: RSUs (Restricted Stock Units) — 9,554 shares (Direct); Options To Purchase Common Stock — 11,322 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year. The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lalomia Brent

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FL 33773

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive VP RA, QA

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
RSUs (Restricted Stock Units)	$0	03/02/2026		A		9,554		(1)	03/02/2036	Common Stock	9,554	$0	9,554	D
Options To Purchase Common Stock	$45.79	03/02/2026		A		11,322		(2)	03/02/2036	Common Stock	11,322	$0	11,322	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

2. The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.

	/s/ Thomas Fistek for Brent Lalomia by Power of Attorney	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CONMED (CNMD) Executive VP Brent Lalomia report on this Form 4?

He reported receiving equity-based compensation awards, not open-market trades. Lalomia was granted 9,554 restricted stock units and 11,322 stock options on March 2, 2026, under CONMED’s 2025 Long-Term Incentive Plan, aligning part of his pay with future company performance.

How many RSUs did Brent Lalomia receive from CONMED (CNMD)?

He received 9,554 restricted stock units. Each RSU represents a contingent right to one share of CONMED common stock, generally vesting over three years: 33% after one year, 33% after two years, and 34% after three years, subject to the plan’s conditions.

What stock options were granted to Brent Lalomia at CONMED (CNMD)?

He was granted 11,322 options to purchase CONMED common stock. These options were issued with a per-share grant price of $0.00 and generally vest in four equal annual installments, with 25% vesting one year after the March 2, 2026 grant date.

Are the CONMED (CNMD) RSUs granted to Brent Lalomia immediately vested?

No, they are subject to vesting conditions. The 9,554 RSUs generally vest over a three-year period, in 33%, 33%, and 34% tranches each year following the March 2, 2026 grant date, under the company’s 2025 Long-Term Incentive Plan.

When do Brent Lalomia’s CONMED (CNMD) stock options vest?

They generally vest over four years. The 11,322 options vest in equal 25% installments, with the first quarter vesting one year after the March 2, 2026 grant date, and the remaining three quarters vesting in subsequent years, under the 2025 Long-Term Incentive Plan.

Does the Form 4 show Brent Lalomia buying or selling CONMED (CNMD) shares?

It shows equity awards, not market purchases or sales. The transactions are coded as acquisitions from grants: 9,554 RSUs and 11,322 stock options awarded at a grant price of $0.00 per unit, reflecting compensation rather than trading activity.